^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Neuroendocrine Tumor
    Drug:Mycapssa (octreotide) (SSTR agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pancreatic Neuroendocrine Tumors: Preferred Regimens...Octreotide...Bronchopulmonary/Thymus Neuroendocrine Tumors: Preferred Regimens...lanreotide
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Clin Oncol
    Title:

    Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

    Excerpt:
    ...performed a placebo-controlled, double-blind, phase IIIB study in patients with well-differentiated metastatic midgut NETs....Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072)…
    DOI:
    10.1200/JCO.2009.22.8510
    Trial ID:
    NCT00171873